Small Molecule Compositions for Neurodegenerative Biomarker Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's disease are inadequate in effectively addressing chronic inflammation, amyloid-β plaque deposition, neuronal iron deposition, and hyperglycemia, which contribute to the progression and severity of these conditions.
Innovation Solution
Compositions comprising small molecule biochemicals and their derivatives, administered in combination with other medicaments, are used to modulate markers of neurodegenerative diseases, including peripheral and central inflammation, amyloid-β plaque deposition, neuronal iron deposition, and hyperglycemia, through blood-based biomarker detection and treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neurodegenerative diseases are used, then disease progression is managed, but effectiveness in addressing chronic inflammation, amyloid-β plaque deposition, neuronal iron deposition, and hyperglycemia is inadequate
Solution Approach 1:
The treatment approach is segmented into multiple targeted components: (1) small molecule biochemicals for modulating inflammation markers, (2) specific interventions for amyloid-β plaque deposition, (3) treatments for neuronal iron deposition, and (4) hyperglycemia management. This segmentation allows each harmful factor to be addressed by specialized treatments rather than a single broad- spectrum approach, improving overall treatment effectiveness
Solution Approach 2:
The invention employs parameter changes by administering small molecule biochemicals at specific dosages (e.g., 2.5 mg to 50 mg per 1 kg body weight) to modulate disease markers. The treatment regimen includes adjusting concentrations of biochemicals in serum and erythrocytes to achieve therapeutic effects on inflammation, plaque deposition, iron accumulation, and glucose levels, thereby changing the physiological parameters to counteract harmful factors
2Measurement precision
If blood-based biomarker detection methods are implemented, then detection capability is improved, but cost-effectiveness must be maintained
Solution Approach 1:
The blood-based biomarker detection method utilizes readily accessible blood samples and standard laboratory techniques that are already widely available in clinical settings. The method leverages existing diagnostic infrastructure to detect disease markers without requiring specialized equipment or complex procedures, thereby maintaining cost-effectiveness while improving detection capability
Solution Approach 2:
The detection approach employs simple, disposable blood sampling methods and basic analytical techniques that do not require expensive, maintenance-intensive equipment. By using conventional biomarker assays on routine blood samples, the system achieves improved detection precision through accessible means rather than costly advanced imaging or specialized devices
Data Source
AI summary
Compositions including small molecule biochemicals, and salts and derivatives thereof, and methods for detection, treatment or prophylaxis of neurodegenerative diseases are provided, including compositions and methods for detecting and treating conditions that contribute to neurodegenerative diseases, including peripheral and central inflammation, amyloid-β plaque deposition in the brain, neuronal iron deposition and hyperglycemia.